Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135836 | 0.85 | HTT (0.37) | HTTATMNAMPTALDH1A1L3MBTL1 | |
| SCHEMBL4126131 | 0.85 | HTT (0.37) | HTTATMNAMPTALDH1A1L3MBTL1 | |
| SCHEMBL4131224 | 0.83 | P2RX7 (0.38) | HTTATMNAMPTALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3694577 | 0.82 | HTR6 (0.34) | NAMPTALDH1A1CYP2C9MAPK1P2RX7 | |
| SCHEMBL476366 | 0.82 | NAMPT (0.38) | NAMPTALDH1A1L3MBTL1 | |
| SCHEMBL4137765 | 0.81 | NAMPT (0.33) | NAMPTALDH1A1MAPK1P2RX7PKM | |
| SCHEMBL3698417 | 0.81 | PLCG1 (0.33) | NAMPTCYP2C9P2RX7PTGDR2CNR1 | |
| SCHEMBL476390 | 0.80 | HTT (0.39) | HTTNAMPTALDH1A1TSHRP2RX7 | |
| SCHEMBL4139027 | 0.79 | CNR1 (0.39) | NAMPTCNR1 | |
| SCHEMBL4120239 | 0.79 | HTR6 (0.40) | NAMPTALDH1A1L3MBTL1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | HTT 3967/4885ATM 4850/4885NAMPT 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.